AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04468178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total joint arthroplasty of the glenohumeral joint
Description: The arthroplasty of the glenohumeral joint will be performed as an anatomical reconstruction after primary or post-traumatic osteoarthritis.
Study NCT06301763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oral-esophageal Tube Feeding
Description: During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
Study NCT06301763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasogastric tube feeding
Description: During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The control group is provided with nutritional support as nasogastric tube feeding, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
Study NCT05229549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GOLIKE PLUS 3-16
Description: PKU GOLIKE PLUS 3-16 is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
Study NCT05587322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI5100
Description: Orally via tablet
Study NCT05587322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally via tablet
Study NCT05229549 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Free AAs
Description: It is an immediate-release free AAs mixture with the same qualitative and quantitative composition of PKU GOLIKE PLUS 3-16.
Study NCT05494099 — intervention group
Intervention type: PROCEDURE
Intervention: endoscopic maxillary mega-antrostomy
Description: a mucosal sparing technique that facilitates mucus clearance and sinus irrigation in terminally dysfunctional maxillary sinuses. EMMA involves extending the antrostomy through the posterior half of the inferior turbinate down to the floor of the nose, creating a significantly enlarged antrostomy.
Study NCT05494099 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Modified Medial Maxillectomy
Description: In this approach, the maxillary sinus is operated upon, while the inferior turbinate and nasolacrimal duct are preserved.
Study NCT05494099 — intervention group
Intervention type: PROCEDURE
Intervention: Modified endoscopic pre-lacrimal approach
Description: The approach involves making a curved mucosal incision on the lateral nasal wall just anterior to the head of the inferior turbinate. The nasal mucosa was then undermined off the lateral nasal wall. The maxillary sinus was entered with a chisel, and the medial bony wall of the maxillary sinus removed.
Study NCT06422559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transmagnetic stimulation
Description: Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil
Study NCT05688566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pinnacle trainer
Description: The pinnacle trainer (S776MA, SportsArt, Taiwan) was used in this study.
Study NCT05688566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pinnacle trainer
Description: The pinnacle trainer (S776MA, SportsArt, Taiwan) was used in this study.
Study NCT06119893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: submucosal 8 mg (2 mL) dexamethasone application
Description: The mucoperiosteal flap was applied. After operation, submucosal dexamethasone 8 mg (2 mL) was applied to the operation area as a test group.
Study NCT06119893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: submucosal 2 mL 0.9% isotonic sodium chloride application
Description: The mucoperiosteal flap was applied. After operation, 2 mL 0.9% isotonic sodium chloride was applied to the operation area as a control group
Study NCT05061693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: Oral; Tablet
Study NCT05629026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-biopsies
Description: Two micro-biopsies of limb tissue will be carried out, one on the lymphedema and one in the upper limb not affected.
Study NCT05119959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECD intervention for CHEUs
Description: The bi-weekly community health worker-delivered ECD 1 hour intervention using the modules from the SUPERCDZ curriculum which is a Zambian adaptation of UNICEF's Nurturing Care Framework
Study NCT05119959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for CHEUs
Description: No ECD interventions will be provided by community health workers. Children will be followed at clinics for growth and monitoring, vaccinations on a MoH approved schedule.
Study NCT05061693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral; Tablet
Study NCT06422559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil
Study NCT05185687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: First Come, First Served
Description: Respondents will view the following description of the plan: Tests will be sent out in the order they are requested. People who request tests the quickest will get them first, no matter where they live. People who request tests later may not get any. This strategy is also known as 'First Come, First Served.'
Study NCT05185687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Random
Description: Respondents will view the following description of the plan: People who request tests will be entered into a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live, but some people may not get any tests.
Study NCT05185687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disadvantaged Priority & Random
Description: Respondents will view the following description of the plan: Because COVID-19 has hit people living in disadvantaged areas of the country harder, a proportion of tests will be sent exclusively to people in these zip codes. Planners will allocate 80% of the tests using a random drawing, like a sweepstakes or lottery. Everyone who is in the drawing has the same chance of getting tests, no matter where they live. The remaining 20% are set aside exclusively for the most disadvantaged areas, again allocated with a random drawing. Some people may not get any tests. But people living in disadvantaged areas are more likely to get them.
Study NCT05149287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: single intravenous dose of 1 g of ceftriaxone
Study NCT05149287 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1% lidocaine and saline
Study NCT05140018 — intervention group
Intervention type: PROCEDURE
Intervention: Kidney Transplantation
Description: All participants will receive a kidney transplantation from a living donor or deceased donor
Study NCT05140018 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Immunosuppression
Description: All participants will receive immunosuppresive drugs to prevent rejection of de kidney transplant graft.
Study NCT05140018 — intervention group
Intervention type: PROCEDURE
Intervention: Nephrectomy (kidney donation)
Description: All kidney donors will receive a nephrectomy for kidney donation
Study NCT05578222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200mg i.v. gtt,D1,Q3W,
Study NCT04822961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Senaparib-matched placebo capsules
Study NCT04822961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Senaparib
Description: 20 mg capsules
Study NCT05980988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The experimental phase of this study had last 84 days, and each patient will make 4 visits (d1, d28, d56, d84).
Study NCT05980988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05571657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder/Recall Sent Via Preferred Method of Communication
Description: Parents of 12-17 year-old patients due for COVID-19 booster dose will receive a one-time vaccine reminder/recall via the parent's preferred method of communication (mailed letter, text message, email)
Study NCT06389474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INM004
Description: Two doses of Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab´)2 fragments at a dosage of 4 mg/kg of body weight, 24 hours apart. Each vial contains 25 mg of protein/ml. Therefore, each subject must receive 0.16 ml/kg per dose. The vial volume will be reconstituted in a 100 ml (for subjects with a body weight of 20 kg or more) or 50 ml (for subjects under 20 kg of body weight) infusion bag. It will be administered as an intravenous infusion using an infusion pump over a period of 50 minutes. In subjects with a BMI over 30 kg/m2, infusion will be performed over a period of 100 minutes
Study NCT06389474 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses of placebo, 24 hours apart. The placebo solution has the same composition of excipients as INM004 without the active pharmaceutical ingredient, and its appearance is identical. Each subject must receive 0.16 ml/kg of placebo solution per dose. The vial volume will be reconstituted in a 100 ml (for subjects with a body weight of 20 kg or more) or 50 ml (for subjects under 20 kg of body weight) infusion bag. It will be administered as an intravenous infusion using an infusion pump over a period of 50 minutes. In subjects with a BMI over 30 kg/m2, infusion will be performed over a period of 100 minutes
Study NCT05564702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional drug treatment
Description: The patients in this arm will be given doctor specified dosage.
Study NCT05564702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opt-IVF predicted dosage
Description: The patients in this arm will be given dosage predicted by Opt-IVF.
Study NCT05674071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Articulation/HVT
Description: Osteopathy 1
Study NCT05674071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soft-tissue massage
Description: Osteopathy 2
Study NCT05674071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Craniosacral techniques
Description: Osteopathy 3
Study NCT05674071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination of the three interventions: HVT, soft-tissue and craniosacral techniques
Description: This intervention will use a combination of the three interventions: HVT, soft-tissue and craniosacral techniques
Study NCT05699577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum sample for ELIZA
Description: ELIZA for Ca15-3 and interferon gamma
Study NCT05640882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VRET
Description: 10 week prolonged exposure protocol, using Virtual Reality for imaginal exposure
Study NCT05640882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VRET OLFACTION
Description: 10 week prolonged exposure protocol, using Virtual Reality for imaginal exposure with the addition of olfaction
Study NCT05161663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-driven intervention
Description: This peer-driven intervention (PDI), modified based on respondent-driven sampling (RDS) or snowball sampling, is a chain referral approach. Index peers will be purposefully selected to reflect the diversity of African American (AA) and Hispanic/Latino (H/L) men who have sex with men (MSM) and are required to take a formal training about pre-exposure prophylaxis (PrEP) and HIV. These index peers will educate members of their social networks and encourage them to initiate PrEP. Those referred peers will schedule an appointment to complete a short survey and will be referred to our PrEP clinic if they are interested in PrEP uptake. The referred peers will serve as index peers for the following wave of recruitment. It is expected to achieve a robust sample of AA and H/L within six waves of recruitment. This PDI approach is potential to engage AA and H/L who are most at risk of HIV acquisition in PrEP uptake and could contribute to reducing the concentrated HIV epidemic.
Study NCT05294614 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sonreír es diveritdo - Smiling is fun
Description: Smiling is Fun is an online program with the most effective psychological procedures for depression and other techniques to promote coping ability, emotional regulation and resilience along 8 modules. The modules and their aims are: 1) Motivation for change; advantages and disadvantages of changing and importance of motivation; 2) Understanding emotional problems; psychoeducational information, maintaining factors and management of medication and sleep hygiene; 3) Learning to get going; behavioural activation strategies; 4) Learning to be flexible; how interpret negative thoughts and situations in a more flexible way; 5) Learning to enjoy; importance of positive emotions and strategies to promote them; 6) Learning to live; how to identify the psychological strengths and importance of doing activities based on values and vital goals; 7) Living and learning; putting into practice the strengths identified in previous module; 8) From now on... what?; a relapse prevention module.
Study NCT06542549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: The study treatment was followed by a 3-week treatment cycle. The dosing time window is ±3 days. Within 72 hours before each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, and physical status score, to evaluate the safety and tolerability of continued treatment.
Study NCT04809038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Patient will be placed in a comfortable prone position and encouraged to maintain complete relaxation. The selected active MTrPs was prepared by wiping the area with alcohol pad, and a gauge needle with its plastic guide tube in place will be palced over the active MTrPs .a tapping motion will be used to advance the needle to a depth of 5 to 10 mm for 30 seconds
Study NCT04809038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: magnesium sulphate iontophoresis
Description: The subjects in the iontophoresis group received MgSO4 iontophoresis using an iontophoretic drug delivery system (Phoresor_IIAuto,ModelPM850,IOMED. MTrPs were examined using pincer palpation and marked by pin. MgSO4 was applied to the active positive electrode using a syringe with a concentration of 100 mg/cm2. The active electrode was placed directly over the marked area where the sensitive MTrPs were located. The dispersive electrode was applied to the skin 6 inches distal from the active electrode.
Study NCT04809038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercise
Description: The patient will be placed in a comfortable and relaxed sitting position with his back supported ; one hand was placed on the side of the head applying the stretching force, while the other hand was placed on the patients shoulder applying shoulder stablization . The direction of stretched force was in flexion , side bending to the opposite side and rotation to the same side . The stretched position will be sustained for 30 seconds , then a relaxation period of 30 seconds . This procedure was repeated 3 times .
Study NCT04809038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching exercise
Description: The patient will be placed in a comfortable and relaxed sitting position with his back supported ; one hand was placed on the side of the head applying the stretching force, while the other hand was placed on the patients shoulder applying shoulder stablization . The direction of stretched force was in flexion , side bending to the opposite side and rotation to the same side . The stretched position will be sustained for 30 seconds , then a relaxation period of 30 seconds . This procedure was repeated 3 times .
Study NCT05354700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: HLX07 is a recombinant humanized anti-EGFR monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
Study NCT05354700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 is a recombinant humanized anti-PD-1 monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
Study NCT05354700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin and etoposide
Description: chemotherapeutics
Study NCT01244607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single i.v. administration
Study NCT01244607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-0801
Description: single i.v. administration
Study NCT05350982 — intervention group
Intervention type: DEVICE
Intervention: SalivaBio +/- SaliPac
Description: Sterile collection swab (SalivaBio), Modified dummy (SaliPac)
Study NCT04031066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velmanase Alfa
Description: infusion i.v. treatment
Study NCT04031066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: infusion i.v. treatment
Study NCT05578417 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered.
Study NCT05834257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline for fluid resuscitation
Description: Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to Normal Saline infusion (as clinically prescribed).
Study NCT05834257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PlasmaLyte for fluid resuscitation
Description: Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).
Study NCT05834257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ringer's Lacatate for fluid resusciation
Description: Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
Study NCT06304545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab IV 200mg
Study NCT06304545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Capecitabine PO oxaliplatin IV
Study NCT06304545 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy 50Gy /45Gy /25 fractions
Study NCT05205668 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F-652
Description: IL-22 fusion protein administered intravenously
Study NCT05205668 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously
Study NCT05269017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Devarol S amp containing 200,000 units per 2 ml giving a concentration of 5,000 units per drops for four weeks
Study NCT05269017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide nasal spray
Description: 64 µg per puff in a dose of 1 puff for each nostril twice daily for four weeks
Study NCT06190782 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor+/- chemotherapy combined with local therapy
Description: 1. PD-1 inhibitor +/- Chemotherapy PD-1 inhibitor: all FDA approved PD-1 inhibitor producter is suitable~   First line:~   i. TP: paclitaxel 135-175mg/m2,d1+ DDP25mg/m2, d1-3 or 75mg/m2,d1;q21d (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternative) or ii. PF: DDP Second line (other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.) i. Docetaxel or ii. Irinotecan or iii. Paclitaxel (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternatives)~2. Local therapy i. Radiotherapy GTV=all suspected lesions. SBRT: for lung, liver, adrenal gland, celiac lymphnode metatstases 48Gy/6fx; for spine metastatic disease 30Gy/10Fx; for brain metastases 24Gy/30fx; IMRT: for bone metastatic disease 30Gy/10fx; for esophageal lesion or lesion unsuitable of SBRT 50.4Gy/28fx; ii. Surgery iii. Radiofrequency/microwave ablation